A mouse study and two preprints have examined GHK-Cu given through the nose. They report changes on some behavior tests. They do not establish whether a human nasal spray works for cognition or causes fewer side effects than subcutaneous injections.

Correction, November 18, 2026. The earlier version described a single animal study and said nasal and injected exposure had never been examined in the same report. This update adds two mouse preprints and explains why the animal experiments cannot compare side effects in people.

What the mouse studies found

In a 2024 paper, researchers administered GHK-Cu through the nose to male and female 5xFAD mice, a model of Alzheimer’s disease. The authors reported delayed impairment on behavioral tests and fewer amyloid plaques. The author abstract reports outcomes in that mouse model. [1]

A 2023 preprint in aged C57BL/6 mice reported better maze performance after eight weeks of intranasal GHK-Cu than after nasal saline. Some results varied by sex and when the mice were tested. Both sexes performed better on the final box-maze trial. This was an animal experiment. [2]

What the 2026 preprint can compare

The 2026 preprint studied aged C57BL/6J mice. Its authors reported shorter maze escape times in both sexes after eight weeks of intranasal administration. With five days of intraperitoneal injections, they reported a short-lived improvement in males and no improvement in females. [3]

An intraperitoneal injection goes into the abdominal cavity. The experiment paired that route with a shorter exposure, so it cannot isolate the effect of route. The authors did not measure GHK-Cu concentrations in the brain. These reports also do not establish independent replication across the aged-mouse experiments. [3]

Does this tell us about side effects in people?

The experiments answer specific questions about mouse behavior and brain tissue. None of the sources reviewed here compares nasal spray with subcutaneous GHK-Cu injections in people. They leave human nasal absorption, local irritation, and comparative side effects unresolved.

A skin study would measure a different exposure. Skin outcomes cannot establish nasal absorption or explain how a human nasal product would affect memory. The relevant evidence would be a human study of the same route and formulation measuring the benefit or side effect in question.

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified clinician for individual medical decisions.

References

  1. Behavioral and neuropathological features of Alzheimer's disease are attenuated in 5xFAD mice treated with intranasal GHK peptide.. Aging pathobiology and therapeutics, 2024.
  2. Intranasal GHK peptide enhances resilience to cognitive decline in aging mice. bioRxiv (preprint), 2023.
  3. Middle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs. Research Square (preprint), 2026.